The current studies at the Asthma Research Center are open for enrollment unless otherwise noted. The Asthma Research Center runs multiple studies and each study varies in duration and compensation is up to $2,400 for your time and effort.
To see if you are eligible for any of our studies, please contact us at 617-732-8201 or via e-mail at ARC@partners.org or Click HERE to complete our survey and see if you qualify to participate.
Screening for Participation in Asthma Research Studies
The purpose of the study is to identify subjects for participation in the current asthma research studies listed below and any future studies. The study visit involves gathering information about your asthma and related medical conditions. Participants will be compensated $25-$50 for this visit.
Read More
Investigating Dupilumab’s Effect in Asthma by genotype (IDEA)
This Phase 4 clinical research study is examining the FDA-approved drug Dupixent (Dupilimab) and biomarkers in people with moderate to severe asthma. The study aims to compare the effect that the study drug (Dupixent vs. placebo) has on asthma exacerbations. The study team is looking to understand if the underlying presence of these biomarkers in your blood might indicate a more positive response to the study drug when compared to people who do not have this biomarker present.
Participants should be prescribed Inhaled Corticosteroids (such as Flovent, Pulmicort, QVAR, Advair, or Symbicort).
Participants will have at least 9 visits over an 18-month period. The study will provide all participants with Dulera and study drug for them to self-administer at no cost. Participants will be compensated up to $870.
Read More
ARRIVAL
The ARRIVAL study is being done to see if people with severe asthma who take the study drug, tezepelumab, can reduce maintenance therapy without loss of asthma control. This is a Phase IIIb clinical study sponsored by AstraZeneca.
The study drug tezepelumab, is available under the brand name TEZSPIRE. It is a prescription medicine used as an add-on maintenance treatment for people aged 12 and older with severe asthma.
Participants that qualify after screening period will
begin receiving subcutaneous injections of tezepelumab in
addition to taking their current asthma medications. Participants
will visit the research site every 4 weeks for the injections
and other study tests and procedures.
Study drugs, study visits, and study-related tests and examinations are free of charge. Compensation for participation is up to $2200 and parking during study visits is covered by vouchers for the BWH garages.
Read More
FLAIR
The FLAIR study is investigating a new approach to rescue medications by comparing an Albuterol-only inhaler to a combination inhaler (Fluticasone Propionate and Albuterol). This study will help us learn if this combination inhaler reduces severe asthma attacks compared to standard ‘reliever’ medications. The findings from this study may lead to better treatment options and help other people with asthma in the future. This is a Phase III clinical study sponsored by TEVA Pharmaceuticals.
Participants will have a minimum study treatment period of 24 weeks but for some participants it may be longer. There will be 3 onsite morning visits within the first 6 weeks of the study. After this initial period, onsite morning visits will occur once every 12 weeks with 1 phone call every 4 weeks (between visits).
Participants can expect to complete daily e-diaries (a handheld electronic device) and measure their lung function using a peak flow meter (a small device that you blow air into). Study drug will be provided at no cost. Participants will be compensated up to $600 for their participation. Participants will be given parking vouchers for the BWH garages.
THARROS
The THARROS study is a phase III clinical trial evaluating if inhaled steroids can help reduce the risk of heart and vascular disease in people with COPD. This study will be comparing both FDA approved Breztri – containing budesonide, glycopyrronium, and formoterol fumarate – and a dual therapy of glycopyrronium and formoterol fumarate. These medicines are designed to work together to reduce inflammation, relax the muscles in the airway, and help keep the airways open. We are looking for current or former smokers aged 40-80 with COPD and elevated cardiopulmonary risk who are not currently taking an inhaled steroid.
All participants will start off on the dual therapy at the first in person visit and will take it until their second visit where all eligible participants will be randomly chosen for either the dual therapy or Breztri. They will take this as maintenance for up to 3 years while completing 9 virtual visits with study staff. This study provides maintenance and rescue inhalers for COPD for up to 3 years. Participants will be compensated up to $1300 over 3 years and will be given parking vouchers for the BWH garages.
If you are interested please fill out the short screening survey located at this link, https://redcap.link/COPDscreener. Please contact us with any questions at 617-732-8201 or by e-mail at ARC@partners.org.
AIRCULES
The AIRCULES study is a clinical trial to assess the efficacy, safety, and tolerability of a new add-on therapy in moderate to severe asthma that is not well controlled. By choosing to volunteer for this study, you can help us learn if this new injectable add-on therapy will lead to better asthma control in people with moderate to severe asthma. We are looking for people who take daily maintenance inhalers and have used prednisone (or a similar steroid medication) for symptoms of an asthma attack in the past year. The findings from this study may lead to better treatment options and help other people with asthma in the future. This is a Phase II clinical study sponsored by SANOFI.
Participants will receive an injection of either the investigational drug or a placebo. There will be 16 onsite visits over approximately 12 months. Participants will be asked to complete daily e-diaries (a handheld electronic device) and measure their lung function using a peak flow meter (a small device that you blow air into). The study sponsor will cover copays for approved asthma medications taken by study participants for the duration of the trial. Compensation for participation is up to $2400 and parking during study visits is covered by vouchers for the BWH garages.
Read More
Severe Asthma Research Program (SARP)
The THARROS study is a phase III clinical trial evaluating if inhaled steroids can help reduce the risk of heart and vascular disease in people with COPD. This study will be comparing both FDA approved Breztri – containing budesonide, glycopyrronium, and formoterol fumarate – and a dual therapy of glycopyrronium and formoterol fumarate. These medicines are designed to work together to reduce inflammation, relax the muscles in the airway, and help keep the airways open. We are looking for current or former smokers aged 40-80 with COPD and elevated cardiopulmonary risk who are not currently taking an inhaled steroid.
All participants will start off on the dual therapy at the first in person visit and will take it until their second visit where all eligible participants will be randomly chosen for either the dual therapy or Breztri. They will take this as maintenance for up to 3 years while completing 9 virtual visits with study staff. This study provides maintenance and rescue inhalers for COPD for up to 3 years. Participants will be compensated up to $1300 over 3 years and will be given parking vouchers for the BWH garages.
If you are interested please fill out the short screening survey located at this link, https://redcap.link/COPDscreener. Please contact us with any questions at 617-732-8201 or by e-mail at ARC@partners.org.